Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR3147736

—

da7ef08c-c4a8-517b-87fe-25ececdf41c8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.330
  • FATTY_ACID_METABOLISM+0.310
  • PEROXISOME+0.280
  • P53_PATHWAY+0.240
  • PROTEIN_SECRETION+0.220
  • HEME_METABOLISM+0.210
  • BILE_ACID_METABOLISM+0.160
  • GLYCOLYSIS+0.150
  • ADIPOGENESIS+0.130
  • NOTCH_SIGNALING+0.130

Top 10 suppressed

  • G2M_CHECKPOINT-0.440
  • IL6_JAK_STAT3_SIGNALING-0.400
  • INTERFERON_GAMMA_RESPONSE-0.400
  • ALLOGRAFT_REJECTION-0.370
  • E2F_TARGETS-0.350
  • HEDGEHOG_SIGNALING-0.350
  • INTERFERON_ALPHA_RESPONSE-0.350
  • KRAS_SIGNALING_UP-0.240
  • INFLAMMATORY_RESPONSE-0.230
  • PI3K_AKT_MTOR_SIGNALING-0.220

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1C3L-01889
lung-landscapes@6
—cohortA20.852
2SRR8943024
bladder-landscape@3
——0.837
3SRR8943041
bladder-landscape@3
——0.837
4SRR4296082
lung-landscapes@6
—cohortA10.830
5SRR1313117
breast-umap@18
—B0.815
6SRR6013557
lung-landscapes@6
—cohortA10.814
7MNG1112
mng-umap@100
——0.797
8TCGA-BH-A18S-01A-11R-A12D-07
breast-umap@18
—B0.794
9TCGA-44-6776-01A-11R-1858-07
lung-landscapes@6
—cohortA20.790
1020070161.TNBC
breast-umap@18
—F0.788

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.330Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.310Inavolisib— uncovered
PEROXISOME0.280Idelalisib— uncovered
P53_PATHWAY0.240Idelalisib— uncovered
PROTEIN_SECRETION0.220Remibrutinib— uncovered
HEME_METABOLISM0.210Temsirolimus— uncovered
BILE_ACID_METABOLISM0.160Inavolisib— uncovered
GLYCOLYSIS0.150Inavolisib— uncovered
ADIPOGENESIS0.130Inavolisib— uncovered
NOTCH_SIGNALING0.130Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.090Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.090Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.080Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.080Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.070Inavolisib— uncovered
PANCREAS_BETA_CELLS0.070Cobimetinib— uncovered
COAGULATION0.060Binimetinib— uncovered
DNA_REPAIR0.060Idelalisib— uncovered
HYPOXIA0.050Idelalisib— uncovered
TGF_BETA_SIGNALING0.040Inavolisib— uncovered